Combination of Magrolimab and Rituximab Well Tolerated in Patients With Refractory/Relapsed Indolent NHL
A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events, suggesting long-term safety. The treatment also confirmed magrolimab penetration into the tumor.
Low Hemoglobin, IDH2 Mutation Indicative of Poor Survival in MDS
Results from a retrospective study compared and explored biomarkers associated with outcomes in myelodysplastic syndrome (MDS) with plasma cell neoplasms.
Gaps Apparent in Physicians’ Knowledge of CLL, MCL
Physicians in the US, Germany, and France show gaps in their knowledge of the treatment of of refractory/relapsed chronic lymphocytic leukemia (CLL) and mantle Cell lymphoma (MCL).
Decision-Making in SMA Complicated by Insufficient Treatment Comparison
Clinical decision-making can be difficult for patients with SMA due to the lack of clinical trials comparing treatment options.
Pain in SCD: Are Genetic Variations Responsible?
Genetic variability and sex-specific differences may play a role in sickle cell disease (SCD)-related pain; however, more research is needed.
Patients With B-Cell Cancers Have History of Increased Antimicrobial Use
Danish patients who were diagnosed with certain lymphomas and other B-cell malignancies demonstrated increased antimicrobial use for at least a decade before their diagnosis.
Novel Targeted Therapies Show Superiority in Relapsed/Refractory CLL
A meta-analysis demonstrated the superiority of Bruton tyrosine kinase inhibitors (BKTi) in the overall survival of patients with chronic lymphocytic leukemia compared with other therapies.
